Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-61393215 MAD Study in Healthy Subjects
NCT03007693Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) and panic disorder comparing JNJ-61393215 with Placebo (2 arms). Primary endpoints: Number of Participants with Treatment Emergent Adverse Events up to 4 weeks, Time To Reach The Maximum Plasma Concentration at Day 7 and 11 more. Started Jan 2017; status: completed.
02
Drugs
rocavorexant
03
Conditions
major depressive disorder (MDD)panic disorder
Beyond the preview
Go deeper on NCT03007693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03007693.